STING1 and neoplasm: STING agonists can upregulate the expression of type I IFNs in TME, promote DCs maturation, activate T cells via tumor antigen presentation, and recruit CD8 + T cells and NK cells to the tumor lesion, thereby improving the immunogenicity of TNBC [46].